Literature DB >> 19892483

[Evaluation of the LightCycler 480 real-time PCR system for the measurement of CMV, EBV, HHV-6 and BKV viral loads in whole blood].

D Boutolleau1, C Deback, J Géli, Z Aït-Arkoub, F Angleraud, A Gautheret-Dejean, H Agut.   

Abstract

OBJECTIVE: The Roche LightCycler 480 (LC480) system was evaluated for quantitative molecular diagnosis of opportunistic viral infections caused by human cytomegalovirus (CMV), Epstein-Barr virus (EBV), human herpesvirus 6 (HHV-6), and BK virus (BKV), in comparison with "in-house" real-time PCR assays. PATIENTS AND METHODS: A total of 253 whole blood specimens obtained from transplant recipients were tested.
RESULTS: Both the "in-house" and the LC480 methods were highly correlated (Spearman correlation coefficient Rho> or =0.85; p<0.0001) with an excellent overall qualitative agreement (90.5%) and no significant quantitative difference between both techniques for the four viruses tested. The accuracy of the LC480 protocols were confirmed further by the results obtained with the 44 samples from the Quality Control for Molecular Diagnosis (QCMD) 2008 proficiency panel.
CONCLUSION: The LC480 system constitutes a suitable and versatile real-time PCR platform in a routine laboratory setting for the diagnosis and monitoring of opportunistic viral infections in transplant recipients, by measuring HCMV, EBV, HHV-6, and BKV loads in whole blood samples. Copyright 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19892483     DOI: 10.1016/j.patbio.2009.06.006

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  1 in total

1.  Association between lymphocyte subsets and cytomegalovirus infection status among patients with systemic lupus erythematosus: A pilot study.

Authors:  Ling Qin; Zhifeng Qiu; Evelyn Hsieh; Taoran Geng; Jiuliang Zhao; Xiaofeng Zeng; Lu Wan; Jing Xie; Rayoun Ramendra; Jean Pierre Routy; Taisheng Li
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.